JP2017518959A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017518959A5 JP2017518959A5 JP2016557019A JP2016557019A JP2017518959A5 JP 2017518959 A5 JP2017518959 A5 JP 2017518959A5 JP 2016557019 A JP2016557019 A JP 2016557019A JP 2016557019 A JP2016557019 A JP 2016557019A JP 2017518959 A5 JP2017518959 A5 JP 2017518959A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkoxy
- halogen
- hydroxyl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461952467P | 2014-03-13 | 2014-03-13 | |
| US61/952,467 | 2014-03-13 | ||
| US201462010025P | 2014-06-10 | 2014-06-10 | |
| US62/010,025 | 2014-06-10 | ||
| PCT/US2015/020444 WO2015138895A1 (en) | 2014-03-13 | 2015-03-13 | Hepatitis b core protein allosteric modulators |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019085742A Division JP2019151650A (ja) | 2014-03-13 | 2019-04-26 | Ｂ型肝炎コアタンパク質アロステリックモジュレーター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017518959A JP2017518959A (ja) | 2017-07-13 |
| JP2017518959A5 true JP2017518959A5 (enExample) | 2018-04-26 |
| JP6602311B2 JP6602311B2 (ja) | 2019-11-06 |
Family
ID=54072461
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016557019A Expired - Fee Related JP6602311B2 (ja) | 2014-03-13 | 2015-03-13 | Ｂ型肝炎コアタンパク質アロステリックモジュレーター |
| JP2019085742A Withdrawn JP2019151650A (ja) | 2014-03-13 | 2019-04-26 | Ｂ型肝炎コアタンパク質アロステリックモジュレーター |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019085742A Withdrawn JP2019151650A (ja) | 2014-03-13 | 2019-04-26 | Ｂ型肝炎コアタンパク質アロステリックモジュレーター |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US10183936B2 (enExample) |
| EP (3) | EP3607950A3 (enExample) |
| JP (2) | JP6602311B2 (enExample) |
| KR (1) | KR102363174B1 (enExample) |
| CN (2) | CN106413402B (enExample) |
| AP (1) | AP2016009477A0 (enExample) |
| AU (2) | AU2015229174B2 (enExample) |
| CA (1) | CA2942533C (enExample) |
| CL (1) | CL2016002269A1 (enExample) |
| DK (1) | DK3116316T3 (enExample) |
| DO (1) | DOP2016000233A (enExample) |
| ES (1) | ES2748029T3 (enExample) |
| HR (1) | HRP20191444T1 (enExample) |
| HU (1) | HUE046567T2 (enExample) |
| IL (3) | IL247575B (enExample) |
| MX (2) | MX363600B (enExample) |
| PH (2) | PH12016501762B1 (enExample) |
| PL (1) | PL3116316T3 (enExample) |
| PT (1) | PT3116316T (enExample) |
| RS (1) | RS59430B1 (enExample) |
| SG (2) | SG11201607268UA (enExample) |
| WO (1) | WO2015138895A1 (enExample) |
| ZA (1) | ZA201606209B (enExample) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2794565B1 (en) | 2011-12-21 | 2017-07-26 | Novira Therapeutics Inc. | Hepatitis b antiviral agents |
| CA2881057C (en) | 2012-08-28 | 2020-10-27 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
| JP6466348B2 (ja) | 2013-02-28 | 2019-02-06 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | スルファモイル−アリールアミドおよびｂ型肝炎を処置するための医薬品としてのその使用 |
| HUE033542T2 (en) | 2013-04-03 | 2017-12-28 | Janssen Sciences Ireland Uc | Their use as medicaments for the treatment of N-phenylcarboxamide derivatives and hepatitis B |
| HUE040446T2 (hu) | 2013-05-17 | 2019-03-28 | Janssen Sciences Ireland Uc | Szulfamoiltiofenamid-származékok és gyógyszerként történõ alkalmazásuk hepatitis B kezelésére |
| TW202126620A (zh) | 2013-05-17 | 2021-07-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | 胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途 |
| WO2015011281A1 (en) | 2013-07-25 | 2015-01-29 | Janssen R&D Ireland | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| MX368158B (es) | 2013-10-23 | 2019-09-20 | Janssen Sciences Ireland Uc | Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b. |
| US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| JP6553059B2 (ja) | 2014-02-05 | 2019-07-31 | ノヴィラ・セラピューティクス・インコーポレイテッド | Ｈｂｖ感染の治療のための併用療法 |
| PL3102572T3 (pl) | 2014-02-06 | 2019-04-30 | Janssen Sciences Ireland Uc | Pochodne sulfamoilopirolamidu i ich zastosowanie jako leki do leczenia wirusowego zapalenia wątroby typu B |
| ES2748029T3 (es) | 2014-03-13 | 2020-03-12 | Univ Indiana Res & Tech Corp | Moduladores alostéricos de proteína núcleo de hepatitis B |
| EP3271019A1 (en) | 2015-03-19 | 2018-01-24 | Novira Therapeutics Inc. | Azocane and azonane derivatives and methods of treating hepatitis b infections |
| US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| US10684272B2 (en) * | 2015-07-15 | 2020-06-16 | Agency For Science, Technology And Research | Modulation of hepatitis B virus replication |
| TWI730985B (zh) * | 2015-09-15 | 2021-06-21 | 美商艾森伯利生物科學公司 | B型肝炎核心蛋白質調節劑 |
| AR106192A1 (es) | 2015-09-29 | 2017-12-20 | Novira Therapeutics Inc | Formas cristalinas de un agente antiviral contra la hepatitis b |
| WO2017181141A2 (en) | 2016-04-15 | 2017-10-19 | Novira Therapeutics, Inc. | Combinations and methods comprising a capsid assembly inhibitor |
| CN121974842A (zh) | 2016-05-10 | 2026-05-05 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
| CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| AU2017326356A1 (en) * | 2016-09-15 | 2019-04-11 | Assembly Biosciences, Inc. | Hepatitis B core protein modulators |
| KR20230156818A (ko) | 2016-10-03 | 2023-11-14 | 시질론 테라퓨틱스, 인크. | 화합물, 장치, 및 이의 용도 |
| JP7113009B2 (ja) | 2016-11-07 | 2022-08-04 | アービュタス バイオファーマ コーポレイション | 置換ピリジノン含有三環式化合物およびそれを使用する方法 |
| CN106632177A (zh) * | 2016-12-05 | 2017-05-10 | 万特制药(海南)有限公司 | 雷美替胺中间体的制备方法 |
| PT3587420T (pt) * | 2017-02-23 | 2021-06-04 | Fujian Cosunter Pharmaceutical Co Ltd | Composto tricíclico e suas aplicações |
| BR112019018230A2 (pt) | 2017-03-02 | 2020-07-21 | Assembly Biosciences, Inc. | compostos de sulfamida cíclica e métodos de sua utilização |
| EP3596070A1 (en) | 2017-03-13 | 2020-01-22 | Assembly Biosciences, Inc. | Process for making hepatitis b core protein modulators |
| MA49014A (fr) | 2017-03-21 | 2020-02-05 | Arbutus Biopharma Corp | Dihydroindène-4-carboxamides substitués, leurs analogues et procédés d'utilisation correspondant |
| EP4717317A3 (en) | 2017-06-20 | 2026-06-03 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| KR20200030584A (ko) | 2017-07-21 | 2020-03-20 | 앤타바이오 에스에이에스 | 화합물 |
| MX2020004838A (es) | 2017-11-02 | 2020-10-16 | Aicuris Gmbh & Co Kg | Nuevas indol-2-carboxamidas sustituidas con pirazolopiperidina, de alta actividad, activas contra el virus de la hepatitis b (vhb). |
| EA202091113A1 (ru) | 2017-11-02 | 2020-08-28 | Айкурис Гмбх Унд Ко. Кг | Новые высокоактивные аминотиазолзамещенные индол-2-карбоксамиды, активные в отношении вируса гепатита b (hbv) |
| SG11202007097QA (en) | 2018-03-14 | 2020-08-28 | Janssen Sciences Ireland Unlimited Co | Capsid assembly modulator dosing regimen |
| CN112334137A (zh) * | 2018-05-03 | 2021-02-05 | 埃默里大学 | 用于nash和其他代谢紊乱的孤儿核受体调节剂 |
| CN110627752B (zh) * | 2018-06-25 | 2021-08-17 | 新发药业有限公司 | 一种3-氨甲基四氢呋喃的制备方法 |
| CN108863884B (zh) * | 2018-07-26 | 2020-07-03 | 南京富润凯德生物医药有限公司 | 一种用dast试剂作为消除试剂合成共轭硝基烯取代系列衍生物的方法 |
| TWI869058B (zh) | 2018-07-27 | 2025-01-01 | 加拿大商愛彼特生物製藥公司 | 經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法 |
| WO2020038456A1 (zh) * | 2018-08-23 | 2020-02-27 | 福建广生堂药业股份有限公司 | 三并环类化合物的晶型及其应用 |
| PY1991611A (es) | 2018-11-02 | 2022-03-14 | Aicuris Gmbh & Co Kg | Nueva urea 6,7-dihidro-4h-pirazolo [1,5-a] pirazinas activas contra el virus de la hepatitis b (vhb) |
| PY1991606A (es) | 2018-11-02 | 2022-02-10 | Aicuris Gmbh & Co Kg | Nueva urea 6,7-dihidro-4h-pirazolo [4,3-c] piridinas activas contra el virus de la hepatitis b (vhb) |
| AR117188A1 (es) | 2018-11-02 | 2021-07-21 | Aicuris Gmbh & Co Kg | Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (vhb) |
| AR116947A1 (es) | 2018-11-02 | 2021-06-30 | Aicuris Gmbh & Co Kg | Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas-indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb) |
| UY38434A (es) | 2018-11-02 | 2020-05-29 | Aicuris Gmbh & Co Kg | Nuevas 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activas contra el virus de la hepatitis b (hbv) |
| TWI827760B (zh) | 2018-12-12 | 2024-01-01 | 加拿大商愛彼特生物製藥公司 | 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法 |
| EP3897631A4 (en) | 2018-12-20 | 2022-11-23 | C4 Therapeutics, Inc. | TARGETED PROTEIN BREAKDOWN |
| AU2020223865A1 (en) | 2019-02-22 | 2021-07-15 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
| EP3962909B1 (en) | 2019-04-30 | 2023-10-04 | AiCuris GmbH & Co. KG | Novel oxalyl piperazines active against the hepatitis b virus (hbv) |
| MX2021013086A (es) | 2019-04-30 | 2021-11-17 | Aicuris Gmbh & Co Kg | Nuevas fenil y piridil ureas activas contra el virus de la hepatitis b (vhb). |
| US20220306647A1 (en) | 2019-04-30 | 2022-09-29 | Aicuris Gmbh & Co. Kg | Novel indole-2-carboxamides active against the hepatitus b virus (hbv) |
| KR20220002498A (ko) | 2019-04-30 | 2022-01-06 | 아이쿠리스 게엠베하 운트 코. 카게 | B형 간염 바이러스 (hbv)에 대해 활성인 신규 인돌리진-2-카르복스아미드 |
| BR112021021454A2 (pt) | 2019-05-06 | 2021-12-21 | Janssen Sciences Ireland Unlimited Co | Derivados de amida úteis no tratamento da infecção por hbv ou doenças induzidas por hbv |
| SG11202112590WA (en) * | 2019-05-24 | 2021-12-30 | Assembly Biosciences Inc | Pharmaceutical compositions for the treatment of hbv |
| CN110526878A (zh) * | 2019-09-16 | 2019-12-03 | 成都睿智化学研究有限公司 | 一种2-(噁唑基)乙胺的制备方法 |
| CN111072551A (zh) * | 2019-12-30 | 2020-04-28 | 上海睿瓦科技有限公司 | 催化氢化一步法制取哌啶胺的方法 |
| AU2021261307B2 (en) * | 2020-04-22 | 2026-06-18 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of HBV |
| CN113135848A (zh) * | 2021-04-26 | 2021-07-20 | 深圳市华先医药科技有限公司 | 一种巯基烯酯类化合物的制备方法 |
| CN113636960A (zh) * | 2021-08-24 | 2021-11-12 | 上海皓元医药股份有限公司 | 一种2-(氯磺酰基)环己烷-1-烯甲酸乙酯衍生物的制备方法 |
| CN113717080A (zh) * | 2021-10-09 | 2021-11-30 | 西安瑞联新材料股份有限公司 | 一种4-氯-2-氰基苯磺酰氯的合成方法 |
| CN115353479A (zh) * | 2022-07-27 | 2022-11-18 | 常州琦诺生物科技有限公司 | 一种5-溴-2-碘嘧啶的制备方法 |
| WO2024089216A1 (en) | 2022-10-27 | 2024-05-02 | Syngenta Crop Protection Ag | Novel sulfur-containing heteroaryl carboxamide compounds |
| WO2025069039A1 (en) * | 2023-09-28 | 2025-04-03 | Rajaram Samant | An in situ process for the preparation of primary amine compounds |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1480553A (en) | 1976-06-03 | 1977-07-20 | Pfizer Ltd | Tricyclic sulphonamides |
| JPS58225074A (ja) | 1982-06-25 | 1983-12-27 | Chugai Pharmaceut Co Ltd | ジベンゾオキサゼピン誘導体 |
| GB9109557D0 (en) * | 1991-05-02 | 1991-06-26 | Wellcome Found | Chemical compounds |
| US5512563A (en) | 1993-07-29 | 1996-04-30 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| US20070208166A1 (en) * | 2003-10-24 | 2007-09-06 | Exelixis, Inc. | Tao Kinase Modulators And Method Of Use |
| DE102004004928A1 (de) | 2004-01-31 | 2005-08-18 | Bayer Healthcare Ag | Dibenzoxazepine II |
| EP1937677A1 (en) * | 2005-10-17 | 2008-07-02 | Arcadia Pharmaceuticals Inc. | Cb-1 modulating compounds and their use |
| US20070105835A1 (en) | 2005-11-07 | 2007-05-10 | Kazantsev Aleksey G | Compositions and methods for modulating poly(ADP-ribose) polymerase activity |
| WO2008036139A2 (en) | 2006-06-07 | 2008-03-27 | The Regents Of The University Of California | Inhibitors of mshc and homologs thereof, and methods of identifying same |
| WO2008118141A2 (en) | 2006-10-17 | 2008-10-02 | Acadia Pharmaceuticals Inc. | Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy |
| BRPI0916540B8 (pt) | 2008-07-23 | 2021-05-25 | Us Health | inibidores do canal de ânion de superficíe de plasmódio como agentes antimaláricos |
| CN102791687B (zh) * | 2009-12-18 | 2015-02-11 | 北京凯因科技股份有限公司 | C型肝炎病毒复制的新型抑制剂 |
| WO2012045194A1 (en) | 2010-10-09 | 2012-04-12 | Abbott Laboratories | Benzodiazepinones as fak inhibitors for treatment of cancer |
| WO2013006394A1 (en) * | 2011-07-01 | 2013-01-10 | Institute For Hepatitis And Virus Research | Sulfamoylbenzamide derivatives as antiviral agents against hbv infection |
| US9968650B2 (en) | 2011-07-13 | 2018-05-15 | Indiana University Research And Technology Corporation | Modified viral structural protein with antiviral activity |
| AR089671A1 (es) | 2012-01-06 | 2014-09-10 | Janssen R & D Ireland | 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b |
| CA2881057C (en) | 2012-08-28 | 2020-10-27 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
| NZ704758A (en) | 2012-08-28 | 2018-06-29 | Janssen Sciences Ireland Uc | Fused bicyclic sulfamoyl derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| CA2881322A1 (en) | 2012-09-10 | 2014-03-13 | F. Hoffmann-La Roche Ag | 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| HK1215030A1 (zh) | 2012-11-09 | 2016-08-12 | Indiana University Research And Technology Corporation | 用於hbv組裝效應劑的替代用途 |
| CN104918612B (zh) | 2012-12-06 | 2019-10-25 | 巴鲁克斯布隆伯格研究所 | 作为抗hbv感染的抗病毒剂的官能化苯甲酰胺衍生物 |
| HK1217649A1 (zh) | 2012-12-27 | 2017-01-20 | 德雷克塞尔大学 | 針對hbv感染的新型抗病毒劑 |
| RU2519546C1 (ru) | 2013-01-16 | 2014-06-10 | Общество С Ограниченной Ответственностью "Биоинтегратор" (Ооо "Биоинтегратор") | КОНЪЮГАТЫ И МАЛЫЕ МОЛЕКУЛЫ, ВЗАИМОДЕЙСТВУЮЩИЕ С РЕЦЕПТОРОМ CD16а |
| JP6466348B2 (ja) | 2013-02-28 | 2019-02-06 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | スルファモイル−アリールアミドおよびｂ型肝炎を処置するための医薬品としてのその使用 |
| AR095426A1 (es) | 2013-03-14 | 2015-10-14 | Onyx Therapeutics Inc | Inhibidores tripeptídicos de la epoxicetona proteasa |
| MY181020A (en) | 2013-03-15 | 2020-12-16 | Sanofi Sa | Heteroaryl compounds and uses thereof |
| HUE033542T2 (en) | 2013-04-03 | 2017-12-28 | Janssen Sciences Ireland Uc | Their use as medicaments for the treatment of N-phenylcarboxamide derivatives and hepatitis B |
| PE20151951A1 (es) | 2013-05-17 | 2015-12-26 | Hoffmann La Roche | Heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b |
| HUE040446T2 (hu) | 2013-05-17 | 2019-03-28 | Janssen Sciences Ireland Uc | Szulfamoiltiofenamid-származékok és gyógyszerként történõ alkalmazásuk hepatitis B kezelésére |
| TW202126620A (zh) | 2013-05-17 | 2021-07-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | 胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途 |
| EA031077B1 (ru) | 2013-06-19 | 2018-11-30 | Серагон Фармасьютикалз, Инк. | Модулятор рецептора эстрогена и его применения |
| WO2015017412A1 (en) | 2013-07-29 | 2015-02-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | 11-oxo-10,11-dihydrodibenzo[b,f][1,4]thiazepine s-oxide derivatives and their use as dopamine d2 receptor antagonists |
| ES2748029T3 (es) | 2014-03-13 | 2020-03-12 | Univ Indiana Res & Tech Corp | Moduladores alostéricos de proteína núcleo de hepatitis B |
| KR20170018898A (ko) | 2014-06-10 | 2017-02-20 | 바스프 에스이 | 살진균제로서의 치환된 [1,2,4]트리아졸 및 이미다졸 화합물 |
| TWI730985B (zh) | 2015-09-15 | 2021-06-21 | 美商艾森伯利生物科學公司 | B型肝炎核心蛋白質調節劑 |
| US10811219B2 (en) | 2018-08-07 | 2020-10-20 | Applied Materials Israel Ltd. | Method for evaluating a region of an object |
-
2015
- 2015-03-13 ES ES15761201T patent/ES2748029T3/es active Active
- 2015-03-13 WO PCT/US2015/020444 patent/WO2015138895A1/en not_active Ceased
- 2015-03-13 CN CN201580024580.0A patent/CN106413402B/zh not_active Expired - Fee Related
- 2015-03-13 PH PH1/2016/501762A patent/PH12016501762B1/en unknown
- 2015-03-13 AU AU2015229174A patent/AU2015229174B2/en not_active Ceased
- 2015-03-13 DK DK15761201.1T patent/DK3116316T3/da active
- 2015-03-13 AP AP2016009477A patent/AP2016009477A0/en unknown
- 2015-03-13 US US15/125,911 patent/US10183936B2/en active Active
- 2015-03-13 RS RSP20191187 patent/RS59430B1/sr unknown
- 2015-03-13 KR KR1020167028057A patent/KR102363174B1/ko not_active Expired - Fee Related
- 2015-03-13 JP JP2016557019A patent/JP6602311B2/ja not_active Expired - Fee Related
- 2015-03-13 EP EP19184535.3A patent/EP3607950A3/en not_active Withdrawn
- 2015-03-13 HU HUE15761201A patent/HUE046567T2/hu unknown
- 2015-03-13 PT PT15761201T patent/PT3116316T/pt unknown
- 2015-03-13 PL PL15761201T patent/PL3116316T3/pl unknown
- 2015-03-13 SG SG11201607268UA patent/SG11201607268UA/en unknown
- 2015-03-13 CN CN201910710699.3A patent/CN110437153A/zh active Pending
- 2015-03-13 HR HRP20191444 patent/HRP20191444T1/hr unknown
- 2015-03-13 PH PH1/2021/553231A patent/PH12021553231A1/en unknown
- 2015-03-13 MX MX2016011800A patent/MX363600B/es unknown
- 2015-03-13 EP EP21191660.6A patent/EP3974426A1/en not_active Withdrawn
- 2015-03-13 SG SG10202001506UA patent/SG10202001506UA/en unknown
- 2015-03-13 EP EP15761201.1A patent/EP3116316B1/en active Active
- 2015-03-13 CA CA2942533A patent/CA2942533C/en active Active
-
2016
- 2016-08-31 IL IL247575A patent/IL247575B/en active IP Right Grant
- 2016-09-07 DO DO2016000233A patent/DOP2016000233A/es unknown
- 2016-09-07 ZA ZA2016/06209A patent/ZA201606209B/en unknown
- 2016-09-08 CL CL2016002269A patent/CL2016002269A1/es unknown
- 2016-09-12 MX MX2019003525A patent/MX2019003525A/es unknown
-
2018
- 2018-04-27 US US15/965,655 patent/US10947224B2/en active Active
-
2019
- 2019-04-26 JP JP2019085742A patent/JP2019151650A/ja not_active Withdrawn
- 2019-05-29 AU AU2019203754A patent/AU2019203754A1/en not_active Abandoned
-
2020
- 2020-03-08 IL IL273132A patent/IL273132B/en active IP Right Grant
-
2021
- 2021-01-21 US US17/154,721 patent/US20230019129A1/en not_active Abandoned
- 2021-04-18 IL IL282391A patent/IL282391A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104918612B (zh) | 作为抗hbv感染的抗病毒剂的官能化苯甲酰胺衍生物 | |
| JP6466348B2 (ja) | スルファモイル−アリールアミドおよびｂ型肝炎を処置するための医薬品としてのその使用 | |
| KR101942151B1 (ko) | Hbv 감염에 대한 항바이러스 물질 | |
| JP2024504932A5 (enExample) | ||
| JP2021534124A5 (enExample) | ||
| JP2016121196A5 (enExample) | ||
| JP2018536648A5 (enExample) | ||
| JP2018515495A5 (enExample) | ||
| RU2015107803A (ru) | Производные дигидроксипиримидинкарбоновой кислоты и их применение в лечении, облегчении или предотвращении вирусного заболевания | |
| JP2020533288A5 (enExample) | ||
| JP5822840B2 (ja) | 眼疾患処置薬 | |
| PH12015500758B1 (en) | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases | |
| JP2016534148A5 (enExample) | ||
| JP2018535963A5 (enExample) | ||
| JP2016536316A5 (enExample) | ||
| JP2016512823A5 (enExample) | ||
| US9988390B2 (en) | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
| RU2014143250A (ru) | Производные 7-оксо-тиазолопиридин карбоновой кислоты и их применение при лечении, облегчении или профилактике вирусного заболевания | |
| JP2020507589A5 (enExample) | ||
| WO2013138753A1 (en) | Prodrugs of riluzole and their method of use | |
| JP7159440B2 (ja) | ジカチオン化合物及びその製造方法と使用 | |
| JP2013542267A5 (enExample) | ||
| JP2022552156A5 (enExample) | ||
| JP2018530582A5 (enExample) | ||
| JP2023511152A5 (enExample) |